Terri F. Bruce

Dr. Terri F. Bruce

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Analytica Chimica Acta
Verified
Journal Article
Closed access
SHSisi Huang
Sisi Huang
XJXiaohui Ji
Xiaohui Ji
KJKaylan K. Jackson
Kaylan K. Jackson
DLDavid M. Lubman
David M. Lubman
MAMary B. Ard
Mary B. Ard
R. Kenneth MarcusR. Kenneth Marcus
R. Kenneth Marcus



1 July 2018 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
ARAchyut J Raghavendra
Achyut J Raghavendra
WGWren Gregory
Wren Gregory
TSTyler J Slonecki
Tyler J Slonecki
YDYongchang Dong
Yongchang Dong
IPIndushekhar Persaud
Indushekhar Persaud
RPRamakrishna Podila
Ramakrishna Podila
Background: Although optical spectroscopy promises improved lateral resolution for cancer imaging, its clinical use is seriously impeded by background fluorescence and photon attenuation even in the so-called two-photon absorption (2PA) imaging modality. An efficient strategy to meet the clinical cancer imaging needs, beyond what two-photon absorption (2PA) offers, is to use longer excitation wavelengths through three-photon absorption (3PA). A variety of fluorescent dyes and nanoparticles (NPs) have been used in 3PA imaging. However, their non-linear 3PA coefficient is often low necessitating high excitation powers, which cause overheating, photodamage, and photo-induced toxicity. Doped wide band gap semiconductors such as Mn:ZnS NPs have previously been used for 3PA but suffer from poor 3PA coefficients. Methods: Here, we prepared ZnO NPs with intrinsic defects with high 3PA coefficients using a polyol method. We functionalized them with peptides for selective uptake by glioblastoma U87MG cells and used breast cancer MCF-7 cells as control for 3PA studies. Uptake was measured using inductively coupled plasma-mass spectrometry. Biocompatibility studies were performed using reactive oxygen species and cell viability assays. Results: We demonstrate that ZnO NPs, which have a band gap of 3.37 eV with an order of magnitude higher 3PA coefficients, can facilitate the use of longer excitation wavelengths 950–1,100 nm for bioimaging. We used the presence intrinsic defects (such as O interstitials and Zn vacancies) in ZnO NPs to induce electronic states within the band gap that can support strong visible luminescence 550–620 nm without the need for extrinsic doping. The peptide functionalization of ZnO NPs showed selective uptake by U87MG cells unlike MCF-7 cells without the integrin receptors. Furthermore, all ZnO NPs were found to be biocompatible for 3PA imaging. Conclusion: We show that defect-induced luminescence 550–620 nm in ZnO NPs (20 nm) due to 3PA at longer excitation (975 nm) can be used for 3PA imaging of U87MG glioblastoma cells with lower background noise.

Verified
Journal Article
Open access
PDF file
OOOlanrewaju Oladosu
Olanrewaju Oladosu
IEIkechukwu C. Esobi
Ikechukwu C. Esobi
RPRhonda Reigers Powell
Rhonda Reigers Powell
TBTerri F. Bruce
Terri F. Bruce
ASAlexis Stamatikos
Alexis Stamatikos
Cholesterol-laden macrophages are recognized as a major contributor to atherosclerosis. However, recent evidence indicates that vascular smooth muscle cells (VSMC) that accumulate cholesterol and transdifferentiate into a macrophage-like cell (MLC) phenotype also play a role in atherosclerosis. Therefore, removing cholesterol from MLC may be a potential atheroprotective strategy. The two transporters which remove cholesterol from cells are ABCA1 and ABCG1, as they efflux cholesterol to apoAI and HDL, respectively. In this study, the well-characterized immortalized VSMC line MOVAS cells were edited to generate ABCA1- and ABCG1-knockout (KO) MOVAS cell lines. We cholesterol-loaded ABCA1-KO MOVAS cells, ABCG1-KO MOVAS cells, and wild-type MOVAS cells to convert cells into a MLC phenotype. When we measured apoAI- and HDL-mediated cholesterol efflux in these cells, we observed a drastic decrease in apoAI-mediated cholesterol efflux within ABCA1-KO MOVAS MLC, but HDL-mediated cholesterol efflux was only partially reduced in ABCG1-KO MOVAS cells. Since SR-BI also participates in HDL-mediated cholesterol efflux, we assessed SR-BI protein expression in ABCG1-KO MOVAS MLC and observed SR-BI upregulation, which offered a possible mechanism explaining why HDL-mediated cholesterol efflux remains maintained in ABCG1-KO MOVAS MLC. When we used lentivirus for shRNA-mediated knockdown of SR-BI in ABCG1-KO MOVAS MLC, this decreased HDL-mediated cholesterol efflux when compared to ABCG1-KO MOVAS MLC with unmanipulated SR-BI expression. Taken together, these major findings suggest that SR-BI expression in MLC of a VSMC origin plays a compensatory role in HDL-mediated cholesterol efflux when ABCG1 expression becomes impaired and provides insight on SR-BI demonstrating anti-atherogenic properties within VSMC/MLC.

11 February 2022 in LWT
Verified
Journal Article
Open access
AMA. Morgan
A. Morgan
DDD. Darby
D. Darby
TBTerri F. Bruce
Terri F. Bruce
ARA. Romero
A. Romero
KCK. Cooksey
K. Cooksey